Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients (CONSTAN)

A Phase IIb Study to Explore the Efficacy and Safety of the Concomitant Administration of RUTI® Immunotherapy With the Standard Treatment in Patients With TB

The study is an exploratory clinical trial to evaluate the efficacy and safety of the treatment with a vaccine against tuberculosis (RUTI®) given at the same time as standard treatment in patients with tuberculosis. It is a prospective, randomized (1:1), double-blind, multicentre, placebo-controlled clinical phase IIb trial.

Study Overview

• Status: Withdrawn
• Conditions: Tuberculosis
• Intervention / Treatment: Biological: RUTI® vaccine; Biological: Placebo

Detailed Description

Patients will be randomized (1: 1) to receive an inoculation of RUTI® or placebo at the same time that standard treatment is started.

The standard TB treatment will continue after RUTI® or placebo administration according to SOC guidelines. All the patients will be followed up 6 months after the vaccination or until the end of SOC treatment.

Once all the patients have completed the week 2 follow-up, a Data Safety Monitoring Board (DSMB) will be established to review all relevant safety and toxicity data.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adults (females and males) aged ≥ 18.
2. Written informed consent in a language they understand. This includes informed consent to be in the trial and informed consent to collect specimens.
3. Laboratory confirmed pulmonary TB (with or without extrapulmonary involvement) defined as a hard copy of a sputum laboratory result that reports Mtb detection by sputum-microscopy smear-positive at least 1+, rapid molecular assay or mycobacterial culture.
4. Patients who have not received any anti-tubercular treatment in the last 24 hours.
5. Females of non-childbearing potential: at least 2 years post-menopausal or surgically sterile (e.g. tubal ligation).
6. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrolment and must agree to use highly effective methods of birth control (i.e. diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in the study.
7. Males must agree to use a double-barrier method of contraception (condom plus spermicide or diaphragm plus spermicide) at least 1 month after RUTI/placebo vaccination; or the male patient or his female partner must be surgically sterile (e.g. vasectomy, tubal ligation) or the female partner must be post-menopausal.
8. The patient must be willing and able to attend all study visits and comply with all study procedures.

Exclusion Criteria:

1. Unable to provide written informed consent.
2. Women reported, or detected, or willing to be pregnant during the trial period.
3. Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4.
4. Bodyweight < 40kg.
5. Evidence of rifampicin resistance via GeneXpert.
6. Unstable Diabetes Mellitus as a poor metabolic control within the past 12 months.
7. For HIV infected subjects if the CD4+ count <250 cells/μL.
8. Major co-morbid conditions or any other finding which in the opinion of the investigator would compromise the protocol compliance or significantly influence the interpretation of results (i.e. cancer, immunodeficiency of any nature including treatment with immunosuppressant drugs and excluding HIV infection).

9. Any of the following laboratory parameters:

   • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN);
   • Total bilirubin > 2 x ULN;
   • Neutrophil count ≤ 500 neutrophils / mm3;
   • Platelet count < 50,000 platelets / mm3.
10. Alcohol use: potential participant either self-reports or in the investigator's opinion that the patient drinks more than an average of four units/day over a usual week or is a binge drinker (men: 5 or more drinks; women: consume 4 or more drinks, in about 2 hours).
11. Documented allergy to TB vaccines or any of the study treatment excipients, notably, to the RUTI® vaccine.
12. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A (RUTI); Subjets will receive one inoculation of the RUTI® vaccine at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 mL	Biological: RUTI® vaccine; Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
Placebo Comparator: Group B (Placebo); Subjets will receive one inoculation of normal saline at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region.	Biological: Placebo; Normal saline will be used as a placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Early Bactericidal Activity (EBA) from day 0 to day 14	Measured as the reduction of bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT.	Daily between day 0 and day 14 after treatment initiation and RUTI®/placebo vaccination.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Early Bactericidal Activity (EBA) from 2 to 14 days	Measured as the reduction of bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT. Difference between each intervention arm and control group.	Daily between day 2 and day 14 after treatment initiation and RUTI®/placebo vaccination.
Early Bactericidal Activity (EBA) from 7 to 14 days	Measured as the reduction of the bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT.	Daily between day 7 and day 14 after treatment initiation and RUTI®/placebo vaccination.
Early Bactericidal Activity (EBA) from 4 to 24 week	Measured as the reduction of the bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT	At week 4, 8, 16 and 24 after treatment initiation and RUTI®/placebo vaccination
Hazard ratio for stable culture conversion (SCC).	Difference between each intervention arm and control group.	24 weeks of TB treatment
Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (Days 0-14).	Difference between each intervention arm and control group.	14 days
Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (week 4, 8, 16 and 24 )	Difference between each intervention arm and control group.	Up to week 24
The proportion of patients with AEs between each intervention arm and the control group.	Difference of patients with AEs between each intervention arm and control group.	Up to week 24
The proportion of patients with SAEs between each intervention arm and the control group	Difference of patients with SAEs between each intervention arm and control group.	Up to week 24
Proportion of patients with CLINICAL, X-ray or LABORATORY worsening	Difference of patients with Clinical, X-ray or Laboratory worsening between each intervention arm and control group.	Through study completion, an average of 24 weeks
Proportion of patients with improvement of clinical signs and symptoms, Bandim TB score	Difference of patients with improvement of clinical signs and symptoms between intervention and control group.	At weeks 2, 8, 24
Number of patients with improvement of Health-related Quality of Life (HRQoL) comparing baseline measure with that over the course of therapy.	Difference f patients with improvement of HRQoL between each intervention arm and control group.	At week 8, week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
IFN-γ production of ex vivo stimulated peripheral blood mononuclear cells (PBMC) (Exploratory endpoint for immunogenicity outcomes 1)	Immunogenic properties of the intervention group will be compared to the control group assessed by the evaluation of IFN-γ production of specific immune cells.	Up to week 24
The summative ability of PBMCs to control mycobacterial growth inhibition assay (MGIA) (Exploratory endpoint for immunogenicity outcomes 2)	Immunogenic properties of the intervention group will be compared to the control group assessed by the summative ability of specific immune cells to control mycobacterial growth inhibition.	Up to week 24

Collaborators and Investigators

• Sponsor: Archivel Farma S.L.
• Collaborators: Fundació Institut Germans Trias i Pujol

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2021
• Primary Completion (Actual): June 30, 2022
• Study Completion (Anticipated): December 31, 2022

Study Registration Dates

• First Submitted: November 10, 2021
• First Submitted That Met QC Criteria: November 23, 2021
• First Posted (Actual): November 29, 2021

Study Record Updates

• Last Update Posted (Actual): July 13, 2022
• Last Update Submitted That Met QC Criteria: July 12, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis
• Other Study ID Numbers: AC-R6; 2021-003301-22 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No